Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biomet Spinal Business Expansion Backs 15% Stock Gain In February

This article was originally published in The Gray Sheet

Executive Summary

Biomet's rapidly expanding spinal business and accelerating reconstructive device revenues, coupled with a history of predictable earnings growth, helped the firm's stock advance 15.2% during a generally chilly February for device issues. The stock closed the month at $38.81, a gain of $5.12.

You may also be interested in...

Biomet's $90 Mil. Cash Biolectron Buy Adds SpinalPak Spinal Stimulator

Biomet's $90 mil. cash acquisition of privately-held Biolectron will add the SpinalPak non-invasive spinal stimulator to Biomet's existing orthopedic offerings and complement the firm's SpF implantable spinal fusion stimulation product, Biomet says.

Compounding Pharmacies Sue FDA For Conflating Out-Of-State Dispensing And Distribution In MOU

Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.

What COVID Spotlight Means For Pharma – In Their Own Words

Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem. 




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts